Helping optic nerve cells heal by targeting the mitochondrial protein Armcx1
Regulation of the retinal ganglion cell repair program by the mitochondrial protein Armcx1
Researchers are exploring whether increasing a mitochondrial protein called Armcx1 can help retinal ganglion cells — the eye's nerve cells — survive damage and regrow their axons.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11248340 on NIH RePORTER |
What this research studies
This work looks at how mitochondria are regulated inside retinal ganglion cells (RGCs), the nerve cells that connect your eye to the brain. Scientists will study Armcx1, a mitochondria-linked protein, to see how it affects mitochondrial movement, cell survival, and axon repair in living models. They will manipulate Armcx1 levels and examine whether boosting mitochondrial transport protects RGCs from degeneration and promotes axon regrowth. The findings are meant to identify steps that could be targeted by future drugs to protect vision in conditions like glaucoma and optic neuropathies.
Who could benefit from this research
Good fit: People with conditions that damage retinal ganglion cells, such as glaucoma or inherited optic neuropathies, would be the eventual candidates for therapies based on this research.
Not a fit: People with eye diseases that do not involve retinal ganglion cells (for example, many forms of macular degeneration) or those needing immediate clinical care are unlikely to benefit directly from this basic research.
Why it matters
Potential benefit: If successful, this could point to new treatments that protect retinal ganglion cells and help the optic nerve repair, potentially slowing or reversing vision loss.
How similar studies have performed: Prior animal studies showed that increasing mitochondrial transport can protect RGCs and promote axon regeneration, and targeting Armcx1 builds on this promising preclinical work.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Gospe, Sidney M — Duke University
- Study coordinator: Gospe, Sidney M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.